Mefruside (Baycaron) is a sulphonamide diuretic with some structural resemblance to frusemide and the thiazides. Pharmacological and clinical studies of its action have been largely conducted in Germany where it was developed and marketed in 1968. The makers claim that the drug (a) has a significant antihypertensive effect of its own, (b) has an enhanced Na/K excretion ratio, and (c) has a sustained action with slow onset.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.